Floatz logo

Nivolumab

Epithelioid Sarcoma

Sarcoma Oncology Research Center, LLCmonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Epithelioid Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Zoledronate
University of Florida
Phase 1/2CCC
Epsametostat
Haihe Biopharma Co., Ltd.
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →